Cargando…
Prolonged double antiplatelet therapy vs association of antiplatelet and low dose of anticoagulant therapy: PEGASUS or COMPASS?
Autores principales: | Brunetti, Natale Daniele, De Gennaro, Luisa, Di Biase, Matteo, Caldarola, Pasquale |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859541/ https://www.ncbi.nlm.nih.gov/pubmed/31763434 http://dx.doi.org/10.1016/j.ijcha.2019.100401 |
Ejemplares similares
-
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial
por: Bhatt, Deepak L., et al.
Publicado: (2020) -
Clinical benefit of long-term use of dual antiplatelet therapy for acute myocardial infarction patients with the PEGASUS-TIMI 54 criteria
por: Lee, Kwan Yong, et al.
Publicado: (2022) -
Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach?
por: Brunetti, Natale Daniele, et al.
Publicado: (2020) -
Percutaneous Nephrolithotomy in Patients on Chronic Anticoagulant/Antiplatelet Therapy
por: Nerli, R B, et al.
Publicado: (2012) -
Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)